Shire Takes The Route Of Least Resistance Into Europe With Approved Oral ADHD Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Specialty pharma withdraws marketing application for Noven’s Daytrana patch after regulators request European study, sticks with in-licensed oral drug that’s already approved.